Latest From MannKind Corp.
With only seven letters last year, Office of Prescription Drug Promotion appears to be continuing its enforcement retrenchment as agency reconsiders its approach to Rx communications.
With $800m in upfront cash from United Therapeutics and $400m pegged to approvals for ralinepag, Arena gets capital for its R&D ambitions and a partner of choice to advance its Phase III PAH compound.
Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.
Having previously disclosed in an SEC filing that it acquired a commercial product, Mylan announces it bought TOBI Podhaler for $463m. Biohaven completes second licensing deal with AstraZeneca, while struggling United Therapeutics and MannKind team up.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- MannKind Corp.
- Senior Management
Michael Castagna, CEO
Steven Binder, CFO
David M Kendall, MD, CMO
Patrick McCauley, Chief Commercial Officer
- Contact Info
Phone: (818) 661-5000
30930 Russell Ranch Rd., Ste. 301
Westlake Village, CA 91362
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.